| scholarly article | Q13442814 |
| P50 | author | Annemarie Ziegler | Q67912497 |
| Ana Paula Simões-Wüst | Q61937803 | ||
| P2093 | author name string | B Baumann | |
| J Hall | |||
| O Gautschi | |||
| R A Stahel | |||
| U Zangemeister-Wittke | |||
| B Odermatt | |||
| S H Leech | |||
| R A Olie | |||
| S Tschopp | |||
| P2860 | cites work | bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death | Q24312157 |
| 5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins | Q28369128 | ||
| Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines | Q28469349 | ||
| Mitochondria and apoptosis | Q29547905 | ||
| The Bcl-2 protein family: arbiters of cell survival | Q29618158 | ||
| BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy | Q33865866 | ||
| BCL-2 family: regulators of cell death | Q34468840 | ||
| Prognostic value of bcl-2 expression in invasive breast cancer | Q36081445 | ||
| Expression of apoptosis-regulatory genes in lung tumour cell lines: relationship to p53 expression and relevance to acquired drug resistance | Q36135196 | ||
| Antisense therapeutics | Q38337950 | ||
| Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance | Q38478924 | ||
| Chemosensitisation of malignant melanoma by BCL2 antisense therapy | Q40611574 | ||
| Bcl-2 overexpression results in reciprocal downregulation of Bcl-X(L) and sensitizes human testicular germ cell tumours to chemotherapy-induced apoptosis | Q40970064 | ||
| bcl-2 protein in non-small-cell lung carcinoma | Q42508274 | ||
| Anti-tumor activity of C-raf antisense--correction. | Q53559000 | ||
| Induction of apoptosis in lung-cancer cells following bcl-xL anti-sense treatment. | Q54052685 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 463-471 | |
| P577 | publication date | 2001-03-01 | |
| P1433 | published in | Journal of the National Cancer Institute | Q400279 |
| P1476 | title | Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins | |
| P478 | volume | 93 |
| Q24305959 | A cleaved form of MAGE-A4 binds to Miz-1 and induces apoptosis in human cells |
| Q28741507 | A melanoma molecular disease model |
| Q74179761 | Analysis of ribosyl-modified, mixed backbone analogs of a bcl-2/bcl-xL antisense oligonucleotide |
| Q36334885 | Antisense oligodeoxynucleotide therapy for bladder cancer: recent advances and future prospects |
| Q36275522 | Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic |
| Q35049576 | Antisense oligonucleotide therapy for urologic tumors |
| Q35179429 | Antisense oligonucleotides for cancer therapy-an overview |
| Q36040819 | Antisense oligonucleotides in the treatment of bladder cancer |
| Q36133133 | Antisense therapy for cancer |
| Q34992794 | Antisense therapy for cancer--the time of truth |
| Q35146577 | Apoptosis and melanoma chemoresistance |
| Q35091131 | Apoptosis in hematological disorders. |
| Q35552651 | Apoptosis, Chemoresistance, and Breast Cancer: Insights From the MCF-7 Cell Model System |
| Q59276618 | Apoptotic responses common to cancer and inflammation |
| Q47874582 | Bcl-2 sustains increased mucous and epithelial cell numbers in metaplastic airway epithelium. |
| Q40687579 | Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide |
| Q59296605 | Bcl-XL is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy |
| Q36671167 | Bcl-xL antisense oligonucleotides radiosensitise colon cancer cells |
| Q39661214 | Born to be alive: a role for the BCL-2 family in melanoma tumor cell survival, apoptosis, and treatment |
| Q38361912 | Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents |
| Q37713757 | Chemosensitization of prostate cancer by modulating Bcl-2 family proteins |
| Q42154446 | Combination therapy with PEG-IFN-alpha and 5-FU inhibits HepG2 tumour cell growth in nude mice by apoptosis of p53 |
| Q36783179 | Depletion of telomerase RNA inhibits growth of gastrointestinal tumors transplanted in mice |
| Q37997623 | Design of novel BH3 mimetics for the treatment of chronic lymphocytic leukemia |
| Q41941878 | Expression and function of bcl-2 proteins in melanoma |
| Q36558024 | Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy |
| Q40642517 | Fas ligand downregulation with antisense oligonucleotides in cells and in cultured tissues of normal skin epidermis and basal cell carcinoma |
| Q34569410 | Gene therapy for lung neoplasms. |
| Q33193343 | Gene therapy of lung cancer |
| Q42442790 | Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment. |
| Q53623548 | Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes. |
| Q89473856 | Inhibition of BCL2 Family Members Increases the Efficacy of Copper Chelation in BRAFV600E-Driven Melanoma |
| Q38325760 | Involvement of hTERT in apoptosis induced by interference with Bcl-2 expression and function |
| Q34605205 | MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis |
| Q37301003 | Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside |
| Q26771601 | Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand? |
| Q34334749 | Putative tumor suppressor Lats2 induces apoptosis through downregulation of Bcl-2 and Bcl-x(L). |
| Q30971455 | Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family |
| Q43933934 | Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma |
| Q35551139 | The future of antisense therapy: combination with anticancer treatments |
| Q36458374 | The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer |
| Q47404782 | The role of Bcl-2 family members in the progression of cutaneous melanoma |
| Q35221178 | The role of Bcl-xL in mouse RPE cell survival |
| Q40615175 | Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity |
| Q81672973 | [Combination treatment with antisense oligonucleotides and chemotherapy in vitro] |
Search more.